M&A
confidence high
sentiment neutral
materiality 0.65
ISCO completes $25.25M sale of LCT to ATCC; pro forma shows higher continuing losses
International Stem Cell CORP
- Closed sale of Lifeline Cell Technology to ATCC on Sept 1, 2026; base price $25M + $250K add-back, adjusted to $25.688M.
- Net cash received at closing $21.688M; $2.6M escrow (working capital + indemnity) held as current asset.
- Estimated pre-tax gain on sale $22.174M; after-tax gain $19.316M; income tax payable $258K.
- Pro forma continuing net loss: $1.616M (H1 2026), $3.195M (FY2025), $3.199M (FY2024) vs smaller historical losses.
- Transaction costs $1.027M; intercompany payable of $9.445M from ISCO to LCT forgiven pre-close.